Not for publication, distribution or publication, neither directly nor indirectly, in the United States, Australia, Japan, Canada, South Africa, New Zealand, Singapore, Hong Kong, Switzerland or in any other jurisdiction where publication, distribution or publication of this press release would be illegal or REQUIRE ADDITIONAL REGISTRATION OR OTHER ACTIONS.Published: June 4, 2022, 15:00 Biotech-IgG Equity AB (publ) (“Biotech” or “the Company”) has decided to issue new bonds worth SEK 10 million to further strengthen the Group’s working capital and enable a faster growth journey. The issue can provide the Company with a total of SEK 10 million before issue costs and a memorandum has today been published on the company’s website (www.biotech-equity.se). Both existing shareholders, former bondholders, institutional investors and the general public in Sweden will have the opportunity to subscribe for the new bonds. The bonds will be registered with Swedish Euroclear.
Biotech-IgG Equity AB (publ)
The bond loan amounts to SEK 10,000,000.
It has been decided to subscribe for the bond loan without preferential rights for existing shareholders in Biotech-IgG Equity AB (publ), but all shareholders will be sent a bond offer to be able to participate in the bond.
The bond loan has an annual interest rate of 8.25%.
Interest payments are made quarterly in arrears and will be handled by Swedish Euroclear.
Subscription of bonds takes place in items of SEK 10,000 and a total of 1,000 items will be issued, which adds SEK 10,000,000 to the Company before issue costs.
Registration for subscription
Registration for subscription of bonds must be made by sending the correctly completed registration of interest or submitted to the company at the address below. Notification of subscription must be made to Biotech-IgG Equity AB (publ) and the notification must be received by the company no later than 15:00 on 24 June 2022. Please note that the notification is binding. Only one application form per person will be considered. About several application forms submitted, only the most recent expression of interest will be considered. Incomplete or incorrect completed expression of interest may be disregarded.
PaymentPayment must be made according to instructions on the settlement note that is sent out to those who have received the allocation. Payment must be made no later than three (3) banking days after the issuance of the settlement note.
Bondholder’s preferential legal position
The bonds, when issued, will be debt securities in accordance with the Act (1998: 1479) on the accounting of financial instruments. The bonds are redeemable bonds. In the event of insolvency, the bondholders have priority over other creditors according to Swedish law.
For further information, please contact:
Glenn Renhult, Chairman of Biotech Equity AB (publ) E-mail: [email protected]
Johan Lee Backman, CEO of Biotech Equity AB (publ) E-mail: [email protected] The following appendices are available for download:
Press release (PDF) See the full press release and other news from this company on Cision News.
Do you also want to be seen with your news on Di.se?
Read more about publishing on Di.seBiotech Equity